ArticleESMO real world data and digital oncology2025
Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer.
Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acquired resistance (AR) to immunotherapy following initial response occurs frequently in metastatic non-small-cell lung cancer (mNSCLC). We developed and validated easy-to-apply prognostic score models to identify patients with mNSCLC at greater risk of AR to frontline (1L) anti-programmed cell death protein 1/programmed death-ligand 1 [anti-PD-(L)1] therapy. Materials and methods: Electronic health records of patients with mNSCLC who responded to 1L anti-PD-(L)1 (diagnosed 2015-2023) in the ConcertAI Patient360™ database were analyzed. Multivariable Cox models (monotherapy versus combination) assessing association between baseline prognostic factors and real-world duration of response (rwDoR) were used to develop prognostic scores and stratify patients into low- and high-risk groups. Risk stratification was evaluated using Kaplan-Meier curves, performance metrics, and decision curves. External validation utilized the COTA NSCLC dataset. Results: The majority of patients ( Conclusions: Proposed prognostic score models may facilitate identifying patient subsets at higher risk of AR to 1L anti-PD-(L)1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.